Device Trial Radar · NCT02680158
A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome
Last checked: Nov 20, 2026Latest source record: Apr 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jan 31, 2016
Primary completion
Mar 31, 2016
Study completion Mar 31, 2016
Sponsor
- Lead sponsor
- Oculeve, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 11, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (investigator)
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare acute tear production produced by the Oculeve Intranasal Lacrimal Neurostimulator with two control devices in participants with aqueous tear deficiency.
Conditions
- Dry Eye Syndrome
- Keratoconjunctivitis Sicca
Interventions
Oculeve IntranasalDevice
Oculeve device, intranasal (test) application for approximately 3 minutes.
ShamDevice
Sham device (control), intranasal application for approximately 3 minutes.
Oculeve ExtranasalDevice
Oculeve device, extranasal (control) application for approximately 3 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute Stimulated Tear ProductionTime frame: Day 0 post-application
- Percentage of Participants Who Experienced One or More Device-related Adverse Event (AE)Time frame: Day 0
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Eye Care Group
Waterbury, Connecticut
Virginia Eye Consultants
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.